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Purpose	Malignant clear cell renal carcinoma (ccRCC) is an aggressive tumor highly resistant to chemotherapy
and radiation. Current therapeutic approaches to management of ccRCC have not significantly improved
patient survival, therefore novel therapies are needed. Activated NFκB and STAT3 expression is
associated with ccRCC pathogenesis. The dietary polyphenol curcumin is a well-documented antitumor
agent and a known inhibitor of NFκB and STAT3 activation. Given the lack of effective therapies that
block ccRCC progression, our objective was to examine whether curcumin could suppress the growth
and migration of ccRCC cells, and whether this suppression was mediated via inhibition of NFκB and
STAT3 activity.
Methods	
Human ccRCC cell lines (769-p, 786-o, Caki-1, ACHN and A-498 cells) were exposed to curcumin to
assess the impact of curcumin on ccRCC cell viability. Colony formation assay was used to assess the
effect of curcumin on ccRCC cell renewal capability. Effect of curcumin on apoptosis was determined
by annexin V binding and mitochondrial membrane depolarization assays. The anti-migratory effect of
curcumin on ccRCC cells was assessed using the wound healing assay. Effect of curcumin on NFκB
and STAT3 phosphorylation in 769-p cells was determined by western blot analysis.
Results		In ccRCC cells, curcumin decreased cell proliferation and cell viability, abolished clonogenic property,
induced apoptosis and blocked cellular migration. The growth suppressive and pro-apoptotic effects of
curcumin were accompanied by decreased phosphorylation of NFκB and STAT3.
Conclusions	
The ability of curcumin to induce apoptosis and inhibit migration of ccRCC cells justifies additional
mechanistic and preclinical studies that examine the effect of curcumin or other NFκB and STAT3
inhibitors as potential suppressors of ccRCC tumorigenesis. (J Patient-Centered Res Rev. 2015;2:156-164.)
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The incidence of malignant clear cell renal carcinoma
(ccRCC) has risen in the last two decades, particularly
in African Americans, Hispanics and women. The
standard cytokine-based therapy with interferon-α
(IFN-α) or interleukin-2 has not been effective at
suppressing ccRCC growth (5-year survival less than
10%), and toxicity is common.1 Although the use
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of targeted therapies in the clinical management of
ccRCC has provided benefits in terms of prolonging
progression-free survival, eventually patients develop
resistance and disease recurs.2-4 Therefore, more
effective and less toxic therapeutic agents are needed.
At the molecular level, disruption of several signaling
pathways has been shown to contribute to the
development and progression of ccRCC. Mutations in
the tumor suppressor von Hippel-Lindau gene (VHL)
are common in ccRCC.5,6 The protein product of VHL,
pVHL, functions to suppress transcriptional activity
of hypoxia-inducible factor (HIF)-1α and HIF-2α.
HIFs regulate the expression of genes involved in
cell survival and angiogenesis (transforming growth
Original Research

factor α, platelet-derived growth factor and vascular
endothelial growth factor).7 Thus, the consequence of
an inactive pVHL is increased growth factor expression
and growth factor receptor-mediated signaling. The
increase in receptor-mediated signaling leads to the
activation of transcription factors, including NFκB and
STAT3, which have well-defined roles in promoting
tumor growth.
Increased NFκB activity stimulates the expression of
gene proteins (bcl-2, MMP-2 and MMP-9) critical to
tumor survival and invasion. Indeed, increased NFκB
activity has been correlated with ccRCC progression, and
upregulation of the prosurvival protein bcl-2 in human
ccRCC is a common occurrence.8,9 The highly metastatic
and invasive nature of ccRCC has been attributed to
increased expression of matrix metalloproteinases (e.g.
MMP-2 and MMP-9) that promote the disruption of
extracellular matrices. Expression of bcl-2, MMP-2 and
MMP-9 is regulated by NFκB.
Constitutively activated STAT3 is associated with
tumor progression, angiogenesis and development
of chemotherapy/radiotherapy resistance.10-12 These
effects of STAT3 are believed to be mediated through
upregulation of cyclins, vascular endothelial growth
factor and bcl-2.13 Increased STAT3 expression has
been detected in human ccRCC, and STAT3 was shown
to promote interleukin-6–mediated proliferation of
ccRCC cells.14,15
NFκB and STAT3 are activated by HIF-induced growth
factors and play critical roles in promoting ccRCC
tumorigenesis. To the best of our knowledge, successful
pharmacological targeting aimed at suppressing
HIF-mediated transcription in ccRCC has not been
achieved. For this study we investigated whether the
dietary polyphenol curcumin, a known suppressor of
NFκB and STAT3 transcriptional activity,16,17 would be
effective at suppressing ccRCC tumor cell growth.

MATERIALS AND METHODS

Chemicals and Reagents
Curcumin was purchased from LTK Laboratories
(St. Paul, MN) and Sigma-Aldrich (St. Louis, MO).
786-o, Caki-1, ACHN and A-498 cells were purchased
from American Type Culture Collection (ATCC)
(Manassas, VA). 769-p cells used in this study were either
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provided by Dr. A. Sorokin (Medical College of
Wisconsin, Milwaukee, WI) or purchased from
ATCC. Phospho-p65 NFκB (S536), total-p65 NFκB,
phospho-STAT3 (S727) and total-STAT3 antibodies were
purchased from Cell Signaling Technology (Danvers, MA).
Cell Culture and Assessment of Cell Viability
769-p, 786-o, Caki-1, ACHN and A-498 cells were
maintained in complete growth medium containing
10% fetal bovine serum (FBS). Medium was replaced
every 2–3 days and subculturing done as required. To
assess cell viability, equal number of cells were seeded
in a 96-well plate in complete growth medium. After
an overnight incubation at 37° C, cells were exposed to
vehicle or curcumin in medium containing 0.5% FBS.
In experiments that evaluated the dose-dependency
of curcumin on ccRCC cell viability or on DNA
synthesis, indicated cell lines were exposed to curcumin
(0–200 µM) for 72 hours. In experiments that examined
the time-course of curcumin-induced suppression
of ccRCC cell viability, 769-p cells were exposed
to curcumin (0, 5 or 50 µM) for 1, 2 or 3 days. After
treatment, cell viability was quantitated by using either
the colorimetric MTT assay or the Cell Titer-Glo®
Luminescent Cell Viability Assay (Promega, Madison,
WI) as previously described.18,19 DNA synthesis was
measured by determining bromodeoxyuridine (BrdU)
incorporation into DNA as previously described.20
Colony Formation Assays
Colony formation ability of 769-p cells was determined
as previously described.18 To briefly summarize, 769-p
cells growing in log phase were seeded at a density of
3,000 cells/well in a 6-well plate in complete growth
medium. Cells were allowed to adhere for an overnight
period, following which the medium was replaced with
complete medium containing curcumin (0, 5, 20, 50,
100 or 200 µM). Cells were cultured for approximately
2 weeks, with a medium change (containing fresh
vehicle or curcumin) performed every 4–5 days. Crystal
violet was used to stain and visualize the colonies.
Annexin V Staining Assays
769-p cells were treated with curcumin (0, 5 or 50 µM)
for 24 hours. After treatment, cells were washed with
phosphate-buffered saline and stained with annexin
V-FITC and propidium iodide. Subsequent flow
cytometry was performed as previously described.18
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Western Blotting
769-p cells were treated with curcumin (0, 5, 20 or
50 µM) for 30 minutes. After treatments, protein content
was determined in the cellular lysates and an equal
amount of protein subjected to electrophoresis, followed
by western blotting with the indicated antibodies as
previously described.18 The pixel intensities of the
western blot bands (p-p65 NFκB, t-p65 NFκB, p-STAT3
and t-STAT3) were quantitated using the intensity plot
and area calculation functions of the ImageJ program
available from the National Institutes of Health (http://
rsbweb.nih.gov/ij/). After normalization to the band
intensities of total proteins (t-p65 NFκB and t-STAT3),
p-p65 NFκB and p-STAT3 protein expressions were
calculated. The control (vehicle-treated sample) was
assigned an arbitrary value of 1, and fold change in the
curcumin-treated groups was calculated.
Mitochondrial Membrane Depolarization Assays
769-p cells were treated with curcumin (0, 5 or 50 µM)
for 24 hours. Cells were washed, stained with JC-1 dye,
and then analyzed by flow cytometry, according to the
manufacturer’s protocol (Cell Technology, Fremont,
CA) as previously described.18
Wound Healing Assay
Wound healing assay for migration was performed as
previously described.21 Briefly, 769-p cells were grown
to monolayer confluency in 6-well plates. A sterile p200
pipette tip was used to inflict a scratch wound. Cellular
debris was removed by washing, and subsequently phase

contrast microscopy was used to capture an image of the
wound. Impact of 24-hour curcumin treatment (0, 5 or
50 µM) on wound closure in 769-p cells was assessed.

RESULTS

Curcumin Inhibits ccRCC Cell Proliferation
and Viability
We initially investigated whether curcumin was effective
in suppressing the growth of ccRCC cell lines. To address
this, we evaluated the concentration-dependent effect of
curcumin on cell viability in a panel of human ccRCC
cell lines. 769-p, 786-o, Caki-1, ACHN and A-498 cells
were treated with curcumin and cell viability assessed.
Our data demonstrated that in all five human ccRCC
cell lines, curcumin was able to significantly (P<0.05)
suppress cell viability (Figure 1), with maximal (>90%)
growth suppression in the concentration range of
50–200 µM. In 769-p cells significant (P<0.05) growth
suppression was also detected at a lower concentration
(20 µM). Although of a small magnitude (~13%), we
did detect a significant (P<0.05) growth stimulation
in A-498 cells in response to a lower concentration
(10 µM) of curcumin.
It has been reported that genetic or epigenetic variations
in VHL can be detected in approximately 90% of human
RCC cases.22 Given that 769-p cells do not express VHL
mRNA, we used this VHL-deficient system for our
subsequent studies that examined the mechanism by
which curcumin suppressed ccRCC cell growth.23

Figure 1. Curcumin inhibits

ccRCC cell proliferation and
viability. 769-p cells (A), Caki-1
cells (B), 786-o cells (C), ACHN
cells (D) and A-498 cells (E)
were treated with the indicated
concentrations of curcumin.
After 3 days cell viability was
detected using the Cell Titer-Glo
Luminescent Cell Viability Assay.
Data were calculated as percentage
of vehicle control, and are the
mean (± standard error of the
mean, SEM) of three independent
experiments. Asterisks (*) designate
a significant difference (P<0.05) from
control values.
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We next examined the kinetics of curcumin-induced
inhibition of 769-p cell proliferation. Our data showed
that compared to vehicle treatment, 5 µM curcumin had
no significant effect on 769-p cell proliferation at either
the early time points or later time points (Figure 2A).
On the other hand 50 µM curcumin had a significant
inhibitory effect on cell proliferation as early as 1 day,
and this inhibitory effect persisted up to 3 days.

Figure 2. Curcumin inhibits ccRCC cell proliferation

in a time-dependent manner. A: 769-p cells were
treated with vehicle control, or 5 or 50 μM curcumin for
the indicated times, and cell viability was assessed. Data
are presented as optical density and are the mean
(± SEM) of at least three independent determinations.
Data are representative of two separate experiments
yielding similar results. Asterisks (*) designate a
significant difference (P<0.05) from day 1 control.
B: 769-p cells were treated with indicated concentrations
of curcumin. After 3 days, proliferation was assessed
by the BrdU incorporation assay. Data are presented
as optical density and are the mean (± SEM) of at
least three independent determinations. Data are
representative of two separate experiments yielding
similar results. Asterisks (*) designate a significant
difference (P<0.05) from control values. C: 769-p cells
were treated with indicated concentrations of ferulic
acid or vanillin, and after 2 days cell proliferation was
assessed by the MTT assay. Data are presented as
percentage of control and are the mean (± SEM) of three
independent experiments. The asterisk (*) designates a
significant difference (P<0.05) from control value.
Original Research

To confirm that the growth inhibition detected in the cell
viability assays was due to decreased DNA synthesis, we
examined the effect of curcumin on BrdU incorporation
in 769-p cells. A significant (P<0.05) inhibition of cell
proliferation was detected with 20 µM curcumin, and
maximal suppression of cell proliferation was detected
with 100–200 µM curcumin (Figure 2B).
Curcumin undergoes degradation in serum-depleted
cell culture media, resulting in the formation of
trans-6-(4′-hydroxy-3′-methoxyphenyl)-2,4-dioxo-5hexenal, ferulic acid, feruloyl methane and vanillin.24
Both ferulic acid and vanillin have been reported to
mediate the antioxidant activity of curcumin.25-28
To address the question of whether the growth
suppressive effects of curcumin were mediated by the
degradation products of curcumin, 769-p cells were
treated with the indicated concentration of ferulic acid
and vanillin, and cell proliferation determined after
2 days. Our data showed that 50 µM ferulic acid had no
significant growth suppression of 769-p cells (Figure
2C). Although 50 µM vanillin did suppress 769-p cell
proliferation (<10%), it was approximately ninefold
less effective than curcumin (50 µM) at suppressing
growth of 769-p cells.
Curcumin Blocks Colony Formation Ability,
Induces Apoptosis and Blocks Migration of
ccRCC Cells
Next, we questioned whether curcumin had any effect
on the colony formation ability of 769-p cells. 769-p
cells were seeded in medium containing 10% FBS
and allowed to adhere for 24 hours. The medium was
then replaced with fresh medium containing 10% FBS
together with the indicated concentration of curcumin,
and colony formation was monitored over the ensuing
2 weeks. We observed that 769-p cells have a robust
ability to form colonies and that this is abolished by
curcumin in a concentration-dependent manner, with a
substantial decrease in the number of 769-p cell colonies
detected in presence of 5 µM curcumin (Figure 3A). At
higher concentrations of curcumin (20–200 µM) the
ability of 769-p cells to form colonies was completely
ablated. Therefore, we questioned whether curcumin
would induce apoptosis in ccRCC cells. To test this, 769-p
cells were treated with the indicated concentrations of
curcumin for 24 hours, washed, and incubated with JC-1
dye (a mitochondria-specific dual fluorescence probe)
per manufacturer instructions (Cell Technologies).
www.aurora.org/jpcrr
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Figure 3. Curcumin blocks colony formation ability, induces apoptosis and blocks migration of ccRCC cells.

A: 769-p cells were cultured in medium containing (0–200 μM) curcumin, and colony formation was assessed after
approximately 2 weeks by crystal violet staining. Data shown are from a single experiment that was representative of
three similar experiments yielding similar results. B: 769-p cells were treated with indicated concentration of curcumin
for 24 hours, and cells were washed and labeled with JC-1 dye. Decreased red and increased green fluorescence
intensities were measured by flow cytometry. Quantitative changes in percentage of gated cells are presented as the
mean (± SEM) of three independent determinations. Data are from a single experiment that was representative of two
independent experiments. Asterisks (*) designate a significant difference (P<0.05) from control values. C: 769-p
cells were treated with indicated concentrations of curcumin for 24 hours, subjected to annexin V-FITC and propidium
iodide staining, and analyzed by flow cytometry. Live/dead cell ratios were calculated. Data are presented as
percentage of gated cells and are the mean (± SEM) of three independent determinations. Data are from a single
experiment that is representative of two independent experiments. Asterisks (*) designate a significant difference
(P<0.05) from control values. D: After forming a monolayer, 769-p cells were serum starved from 24–48 hours,
following which a scratch wound was inflicted by using a sterile p200 pipette tip. Cells were then incubated in medium
containing fetal bovine serum (FBS), either in the presence of vehicle (control) or curcumin 5 and 50 μM, for 24 hours.
Bright field microscopy was used to examine the effect of curcumin on FBS-induced cell migration. Data shown are
from a single experiment and representative of three independent experiments.

In vehicle- and 5 µM curcumin-treated cells, 93.31%
and 92.01% of the cells were detected with intact
mitochondrial membranes, respectively. However, in
50 µM curcumin-treated cells, only 29.86% of cells
presented intact mitochondrial membranes while
69.64% of the cell population presented with disruptions
in the mitochondrial membrane (Figure 3B), indicating
increased mitochondrial membrane depolarization.

cells. To test this, 769-p cells were grown to monolayer
confluence and a scratch wound was inflicted. Cells were
incubated overnight in FBS-containing medium together
with either vehicle or curcumin. Our data showed that in
both vehicle- and 5 µM curcumin-treated cells, wound
closure was complete (Figure 3D). However, 50 µM
curcumin significantly inhibited the migration of 769-p
cells, as evidenced by lack of wound closure.

To examine whether the increase in mitochondrial
membrane depolarization would lead to increased
cell death, 769-p cells were treated with the indicated
concentrations of curcumin for 24 hours, and following
trypsinization, annexin V-FITC binding and propidium
iodide staining were analyzed by flow cytometry. Our
results showed that in vehicle- and 5 µM curcumintreated cells, 1.74% and 2.29% of cells, respectively,
underwent apoptosis (Figure 3C). However, treatment
with 50 µM curcumin resulted in 75.49% of cells
undergoing cell death.

Curcumin Decreases Phosphorylation of
NFĸB and STAT3 in ccRCC Cells
Given the important role of NFκB and STAT3 in
ccRCC pathogenesis, and since curcumin has been
shown to suppress NFκB and STAT3 transcriptional
activity, we questioned whether the ability of curcumin
to induce apoptosis in ccRCC cells is accompanied
with decreased NFκB and STAT3 activation. Because
transcriptional activity of NFκB and STAT3 is positively
regulated by phosphorylation, the impact of curcumin
on the phosphorylation status of p65 NFκB and STAT3
was examined by western blotting with antibodies that
specifically detect either the phosphorylated or total
form of p65 NFκB and STAT3. Our data demonstrated

Since ccRCC tumors are highly metastatic, we questioned
whether curcumin would block migration of ccRCC
160 JPCRR • Volume 2, Issue 4 • Fall 2015
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that curcumin significantly (P<0.05) decreased
phosphorylation of p65 NFκB (S536) by 27.18% and
48.71% at concentrations of 20 and 50 µM, respectively
(Figure 4A, 4B). In addition, 20 and 50 µM curcumin
significantly (P<0.05) decreased STAT3 (S727)
phosphorylation in 769-p cells by 31.14% and 48.76%,
respectively (Figure 4C, 4D). The observed decrease
in the phosphorylated forms of p65 NFκB and STAT3
were not due to an effect of curcumin on the expression
levels of p65 NFκB and STAT3 (Figure 4A, 4C).

DISCUSSION

Both in the United States and worldwide, the incidence
of ccRCC and ccRCC-related mortality has increased
over the past decade. The National Cancer Institute
reports that approximately 54,000 new cases of renal
cancer are diagnosed and approximately 13,000 deaths
by renal cancer occur annually. Although ccRCC is
highly resistant to chemotherapy/radiotherapy, a better
understanding of the biology of ccRCC has led to the
identification of several signaling pathways currently
being examined as potential targets. It is now wellestablished that constitutively active STAT3 and NFκB
participate in ccRCC pathogenesis.9,14 Thus, suppression
of STAT3 and NFκB provides a novel therapeutic
approach to suppressing ccRCC cell proliferation. Given
the lack of effective therapies for ccRCC, and the welldocumented ability of the dietary polyphenol curcumin
to suppress STAT3- and NFκB-mediated signaling, we
examined whether ccRCC tumor suppression could be
achieved with curcumin. It is also of interest to note that
the age-adjusted incidence of kidney cancer in the United
States is the highest in the world and approximately

six times greater than rates in Asian countries where
curcumin is regularly consumed through diet. Our in
vitro study reveals that curcumin is effective at inducing
apoptosis and suppressing migration of ccRCC cells.
In vitro characterization of the growth suppressive effects
of curcumin in ccRCC cells revealed that curcumin, in a
concentration- and time-dependent manner, suppressed
769-p cell viability and colony formation ability, induced
apoptosis and blocked migration. We confirmed that the
growth suppressive effect of curcumin was not cell typespecific, as in addition to the 769-p cells, curcumininduced growth suppression was detected in a panel
of human ccRCC cell lines, including Caki-1, 786-o,
ACHN and A-498 cells. We also examined the ability
of curcumin to suppress the growth of RENCA (mouse
renal carcinoma cells) and observed a similar growth
suppressive pattern (data not shown). Of particular
significance is the ability of curcumin to suppress the
growth of IFN-α–resistant 786-o cells.29 Our future
studies will examine whether curcumin sensitizes
IFN-α–resistant ccRCC cells to IFN-α–induced growth
suppression.
We next questioned whether curcumin would decrease
viability of normal renal proximal epithelial tubule cells.
We observed that curcumin failed to induce apoptosis
in cultured normal rat renal tubular epithelial cells (data
not shown). Our observations are consistent with both
in vitro and in vivo studies demonstrating a protective
effect of curcumin on renal tubular epithelial cells.30,31
Taken together, our data clearly showed that curcumin
could be an effective growth suppressor of ccRCC cells.

Figure 4. Curcumin decreases phosphorylation

and transcriptional activity of NFκB and STAT3
in ccRCC cells. 769-p cells were treated with the
indicated concentrations of curcumin for 30 minutes,
and cell lysates were subjected to western blotting
with anti-phospho p65 NFκB antibody (A, top) and
anti-total p65 NFκB antibody (A, bottom), or antiphospho STAT3 antibody (C, top) and anti-total STAT3
antibody (C, bottom). Data presented are from a
single experiment and representative of three
independent experiments. Western blots from all
three experiments were quantified as described in
the text. Fold change in expression of p-p65 NFκB
(B) and p-STAT3 (D) from control (0 μM curcumin)
was determined. Data are the mean (± SEM) of three
independent experiments. Asterisks (*) designate a
significant difference (P<0.05) from control values.
Original Research
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In most cases metastasis has already occurred when
ccRCC is diagnosed. Therefore, the ability of curcumin
to block cell migration of ccRCC cells was examined.
Our wound healing assay data showed that curcumin
was effective at blocking serum-induced wound closure.
Since degraded curcumin is known to yield dietary
ferulates, especially in buffered medium and serumfree medium, we questioned whether the growth
suppressive effects of curcumin we observed were due
to the generation of ferulic acid and vanillin. However,
because 50 µM ferulic acid had no significant growth
suppressive effect on 769-p cell viability and vanillin’s
modest growth suppressive effect on 769-p cell viability
was approximately nine times less than curcumin at an
equimolar concentration, we concluded that the growth
suppressive effect of curcumin on ccRCC cell viability
is not mediated by its degradation products, suggesting
a direct effect of free curcumin. Our conclusion would
be consistent with a response to a query raised from
a recent article that described the antitumor effects of
curcumin in pancreatic cancer patients.32 In their rebuttal
the authors demonstrated that the suppressive effect of
curcumin on tumor necrosis factor-α–activated NFκB
in human myeloid cells is not mediated by dietary
ferulates, as both ferulic acid and vanillin failed to block
NFκB activation by this protein.
Phosphorylation of the p65 subunit of NFκB regulates
the DNA binding and transcriptional activity of
NFκB.33 Likewise, in melanocytic cells, constitutively
phosphorylated STAT3 has been shown to accumulate
in the nucleus and promote cell survival.34 In examining
the impact of curcumin on NFκB- and STAT3-mediated
transcription in ccRCC cells, we found there is a
robust expression of constitutively phosphorylated p65
NFκB and STAT3 in 769-p cells. Further, when 769-p
cells are exposed to curcumin, a rapid decrease in the
phosphorylation of transcription factors p65 NFκB
and STAT3 was observed. Although our data clearly
showed that curcumin decreases STAT3 and NFκB
phosphorylation, the mechanism of this suppression in
ccRCC cells remains to be determined. One of the key
kinases that phosphorylate p65 NFκB is IKKα, which
phosphorylates p65 NFκB on serine 536.35 In multiple
myeloma cells, curcumin inhibited constitutively
activated IKK.36 It is possible the observed decrease
in p65 NFκB phosphorylation in ccRCC cells could
be due to curcumin-induced suppression of IKKα
162 JPCRR • Volume 2, Issue 4 • Fall 2015

activity. Likewise, the inhibitory effect of curcumin
on STAT3 phosphorylation could involve suppressing
receptor-associated Janus kinase(s) or the nonreceptor
tyrosine kinase Src. Interestingly, Yonezawa et al.
demonstrated the suppression of RCC cell growth by
Src kinase inhibitor PP1 and that this was accompanied
with decreased STAT3 activation.37 Our future studies
will examine the role of IKKα and Src in mediating the
growth suppressive effects of curcumin in ccRCC cells.
Recent studies suggested the potential of targeting
NFκB and STAT3 signaling axes in ccRCC as
novel therapeutic approaches.38,39 To this end, the
proteasome inhibitor bortezomib induced apoptosis in
ccRCC cells in a NFκB-dependent manner; however,
just the suppression of NFκB was not sufficient to
induce apoptosis in ccRCC cells, demonstrating the
requirement of engaging additional signaling targets
in inducing apoptosis in ccRCC cells.40 It is reasonable
to conclude that the ability of curcumin to target two
essential signaling arms in ccRCC, STAT3 and NFκB,
might be the underlying basis of its pro-apoptotic effect.
Although curcumin is an effective and selective
(i.e. targets tumor cells but not normal cells41,42)
antitumor agent, its use in a clinical setting has been
limited, primarily due to its well-documented poor
pharmacokinetic profile. To overcome this limitation,
novel approaches to enhancing the bioavailability of
curcumin are now the focus of several studies. These
include coadministration of curcumin and piperine (an
inhibitor of glucuronidation), which resulted in a 2,000%
increase in bioavailability of curcumin.43 Another
approach has led to the generation of nanoparticles
of curcumin. Nanoparticle curcumin was effective at
suppressing the growth of MCF-7 breast cancer cells,44
and at inhibiting NFκB activity and inducing apoptosis in
human pancreatic tumor cell lines.45 Liposomal curcumin
also was shown to be an effective anticancer agent in
a pancreatic cancer xenograft model.46,47 Additionally,
complexing curcumin with micelles or phospholipids
has proved to improve its bioavailability.48,49 Finally,
synthetic curcumin analogs (e.g. EF-24, HO-3867)
were reported to have increased bioavailability when
compared to curcumin and are more effective than
curcumin at suppressing tumor growth.50,51 Interestingly,
following an intraperitoneal administration of HO-3867
in rats, the synthetic curcumin analog was detected in
the blood, liver, stomach and kidney.51
Original Research

Given the excellent safety profile of curcumin, and the
recent efforts aimed at enhancing its bioavailability, we
anticipate that clinical trials examining the efficacy of
curcumin or its synthetic analogs in suppressing ccRCC
tumorigenesis will be conducted.

CONCLUSIONS

We report a robust growth suppressive and proapoptotic in vitro effect of curcumin on ccRCC cells.
Although in vitro findings do not necessarily translate
into clinical care, if the growth suppressive effects of
curcumin on ccRCC are validated in clinical trials,
this therapeutic approach could complement existing
therapies.
Patient-Friendly Recap
• Curcumin, a commonly used food additive in
Southeast Asia, is known to inhibit the growth
of several types of cancer cells in experimental
settings.
• The authors studied whether curcumin could
block growth and migration of malignant kidney
cancer cells.
• The authors found that curcumin decreased the
viability of kidney cancer cells as well as their
ability to migrate.
• Given its few side effects, curcumin (or its
synthetic analogs) could be considered for
clinical trials aimed at deveoping novel therapies
for kidney cancer.
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